龙丰集团递表港交所 为香港最大的药品零售商

Company Overview - Long Fung Group Holdings Limited is a leading retail pharmacy and cosmetics operator based in Hong Kong, with a market share of 5.2% in retail sales as of 2024, making it the largest pharmacy retailer in Hong Kong [3] - The company operates 29 retail stores and various online sales platforms, offering a wide range of products across 11 categories, including traditional Chinese medicine, Western medicine, health supplements, skincare, cosmetics, and household goods [3][4] - The flagship store located in Mong Kok has a total floor area of approximately 17,500 square feet, making it the largest cosmetics retail store in Hong Kong by total floor area in 2024 [3] Product Offering - The company has sold over 46,000 product SKUs during the historical record period and plans to offer approximately 28,800 SKUs in the fiscal year 2025, including over 3,000 pharmaceutical products, more than 4,200 health products, and over 6,800 beauty products [5][6] - The company has established over 40 private label brands, with more than 700 SKUs available for sale in the first quarter of the fiscal year 2026 [6] Financial Performance - The company's revenue for the fiscal years 2023, 2024, 2025, and the first quarter of 2026 is approximately HKD 1.094 billion, HKD 2.021 billion, HKD 2.460 billion, and HKD 697 million respectively [7] - The profit figures for the same periods are approximately HKD -27.14 million, HKD 145 million, HKD 170 million, and HKD 47.76 million [8] - The gross profit margins for the fiscal years 2023, 2024, 2025, and the first quarter of 2026 are 24.9%, 29.3%, 31.6%, and 31.9% respectively [9] Industry Overview - The total retail sales of consumer goods in Hong Kong are projected to grow from HKD 326.5 billion in 2020 to HKD 376.8 billion in 2024, with a compound annual growth rate (CAGR) of 3.6% [11] - The retail sales of consumer goods are expected to reach HKD 457.5 billion by 2029, with a CAGR of 4.8% from 2025 to 2029 [11] - The pharmaceutical market in Hong Kong is expected to grow from approximately HKD 5.8 billion in 2020 to HKD 8.5 billion in 2024, driven by an aging population and increased healthcare spending, with a CAGR of 10.1% [15]